Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2020-04-24 Major Shareholding Noti…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Flaggemelding Gentian Diagnostics AS
Major Shareholding Notification Classification · 99% confidence The document is titled "Flaggemelding" (Flagging Announcement) and details a transaction where a fund managed by Storebrand Asset Management AS acquired 800,000 shares in Gentian Diagnostics AS, resulting in ownership of 8.66% of the registered share capital. This type of announcement, reporting a change in significant share ownership that crosses a threshold, directly corresponds to the definition of Major Shareholding Notification (MRQ). The short length (304 characters) confirms it is an announcement, not a comprehensive report.
2020-04-24 Norwegian
Melding vedrørende handel
Major Shareholding Notification Classification · 99% confidence The document text is a short announcement in Norwegian ('Melding vedrørende handel') detailing a transaction where Holta Life Sciences AS sold 800,000 shares in Gentian Diagnostics AS. It specifies the remaining ownership percentage (7.89%) and includes commentary from Kjetil Holta regarding the investment history and future strategy. This content directly relates to insider transactions or significant changes in share ownership by an executive/related party. This aligns best with the 'Director's Dealing' (DIRS) category, which covers personal share transactions by directors and executives, or potentially 'Major Shareholding Notification' (MRQ) due to the change in significant ownership. Given the context of an owner/chairman commenting on the sale of a large block of shares, DIRS is the most precise fit, as it often encompasses related-party transactions that signal insider activity or strategic shifts by major shareholders connected to management. The document length is short, but it is the primary announcement of the transaction itself, not an announcement *about* a report.
2020-04-24 Norwegian
First quarter 2020 financial report
Investor Presentation Classification · 98% confidence The document is titled 'Q1 Presentation 2020' and contains an agenda listing 'Q1 Financials' and 'Outlook'. It presents key financial highlights for Q1 2020 (e.g., Sales revenues of MNOK 16.2 in 1Q20) and discusses product pipelines and clinical studies. This structure—a presentation format covering quarterly financial results, operational updates, and future outlook—is characteristic of an Investor Presentation (IP). It is not a full regulatory report (like 10-K or IR) nor is it merely an announcement of a report (RPA/RNS).
2020-04-24 English
First quarter 2020 financial report
Earnings Release Classification · 99% confidence The document explicitly states "First quarter 2020 results" in the title and throughout the text. It provides detailed financial performance metrics (Sales, COGS, EBITDA, Net Profit) comparing Q1 2020 with Q1 2019, and includes a Statement of Comprehensive Income for Q1 2020. This structure and content clearly identify it as a comprehensive financial report for a period shorter than a year, which corresponds to an Interim/Quarterly Report. Q1 2020
2020-04-24 English
First quarter 2020 financial report
Earnings Release Classification · 100% confidence The document explicitly states it is announcing the 'First quarter 2020 financial report' and provides key highlights (sales revenues, growth percentages). Crucially, it ends with the statement: 'Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.' This structure—providing highlights and announcing the availability of the full report—fits the definition of an Earnings Release (ER) which is the initial announcement of periodical financial results (key highlights only). Although it mentions the report is enclosed, the primary function here is the release of the summary results, making ER more appropriate than RPA, which is usually a standalone announcement about the *timing* of a report release without the highlights themselves. Since it is a quarterly report summary, IR (Interim/Quarterly Report) is for the comprehensive report itself, not this announcement summary. Q1 2020
2020-04-24 English
Calprotectin, a promising biomarker for prediction of severe events in sepsis
Regulatory Filings Classification · 95% confidence The document is a short announcement from Gentian Diagnostics AS regarding the publication of a study about calprotectin as a biomarker for sepsis severity. It details the study's aim, methodology, and key findings, concluding with contact information. The document is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV). Since it announces the publication of research/information that is not explicitly covered by other categories (like ESG, Audit, or Management Discussion), and it is a general announcement, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory/company update, or potentially 'LTR' if the publication itself is considered a form of disclosure related to their product/research, but RNS is the most appropriate general catch-all for non-standard announcements. Given the content is a scientific publication announcement, and not a standard financial filing, RNS (Regulatory Filings - general/miscellaneous) is the most suitable classification.
2020-03-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.